
1. curr opin virol. 2019 apr;35:57-62. doi: 10.1016/j.coviro.2019.04.002. epub 2019 
may 21.

nucleoside analogues treatment coronavirus infections.

pruijssers aj(1), denison mr(2).

author information: 
(1)department pediatrics, vanderbilt university school medicine, nashville,
tn, united states; elizabeth b. lamb center pediatric research, vanderbilt
university school medicine, nashville, tn, united states.
(2)department pediatrics, vanderbilt university school medicine, nashville,
tn, united states; elizabeth b. lamb center pediatric research, vanderbilt
university school medicine, nashville, tn, united states; department of
pathology, microbiology, immunology, vanderbilt university school of
medicine, nashville, tn, united states. electronic address:
mark.denison@vumc.org.

recent outbreaks sars-coronavirus mers-coronavirus (cov) heightened
awareness lack vaccines antiviral compounds approved for
prevention treatment human potential zoonotic covs. anti-cov drug
development long challenged activity 3' 5' proofreading
exoribonuclease unique covs. recently, promising nucleoside analogue with
broad-spectrum activity covs identified. review will
discuss progress made development antiviral nucleoside nucleotide
analogues targeting viral rna synthesis effective therapeutics cov
infections propose promising strategies combination therapy.

copyright Â© 2019. published elsevier b.v.

doi: 10.1016/j.coviro.2019.04.002 
pmcid: pmc7102703
pmid: 31125806  [indexed medline]

